81_FR_54973 81 FR 54814 - National Indian Health Outreach and Education II Program; Correction

81 FR 54814 - National Indian Health Outreach and Education II Program; Correction

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Indian Health Service

Federal Register Volume 81, Issue 159 (August 17, 2016)

Page Range54814-54815
FR Document2016-19597

The Indian Health Service published a document in the Federal Register on July 15, 2016, for the Fiscal Year 2016 National Indian Health Outreach and Education II Program. The notice contained an incorrect Announcement Number.

Federal Register, Volume 81 Issue 159 (Wednesday, August 17, 2016) 
[Federal Register Volume 81, Number 159 (Wednesday, August 17, 2016)]
[Notices]
[Pages 54814-54815]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-19597]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Indian Health Service


National Indian Health Outreach and Education II Program; 
Correction

AGENCY: Indian Health Service, HHS.

ACTION: Notice; correction.

-----------------------------------------------------------------------

SUMMARY: The Indian Health Service published a document in the Federal 
Register on July 15, 2016, for the Fiscal Year 2016 National Indian 
Health Outreach and Education II Program. The notice contained an 
incorrect Announcement Number.

FOR FURTHER INFORMATION CONTACT: Ms. Michelle EagleHawk, Deputy 
Director, Office of Direct Service and Contracting Tribes, 5600 Fishers 
Lane, Mail Stop: 8E17, Rockville, Maryland 20857, Telephone: (301) 443-
1104, email:

[[Page 54815]]

[email protected]. (This is not a toll-free number.)

Correction

    In the Federal Register of July 15, 2016, FR Doc. 2016-16819, on 
page 46100, in the second column at the top of the page, the correct 
Announcement Number should read as follows:
    Announcement Number: HHS-2016-IHS-NIHOE-2-BH-HIV-AIDS-0001.

    Dated: August 4, 2016.
Elizabeth A. Fowler,
Deputy Director for Management Operations, Indian Health Service.
[FR Doc. 2016-19597 Filed 8-16-16; 8:45 am]
 BILLING CODE 4165-16-P

54814 Federal Register / Vol. 81, No. 159 / Wednesday, August 17, 2016 / Notices marieann.brill@fda.hhs.gov or FDA possible safety signal regarding the use disability, please contact Marieann Brill Advisory Committee Information Line, of the drug product Exjade (deferasirox) at least 7 days in advance of the 1–800–741–8138 (301–443–0572 in the in children with fever and dehydration meeting. Washington, DC area). A notice in the that was discussed at the September FDA is committed to the orderly Federal Register about last minute 2015 PAC meeting. conduct of its advisory committee modifications that impact a previously For the products to be discussed at meetings. Please visit our Web site at announced advisory committee meeting the PAC meeting, FDA intends to make http://www.fda.gov/ cannot always be published quickly background material available to the AdvisoryCommittees/ enough to provide timely notice. public no later than 2 business days AboutAdvisoryCommittees/ Therefore, you should always check the before the meeting. If FDA is unable to ucm111462.htm for procedures on Agency’s Web site at http:// post the background material on its Web public conduct during advisory www.fda.gov/AdvisoryCommittees/ site prior to the meeting, the background committee meetings. default.htm and scroll down to the material will be made publicly available Notice of this meeting is given under appropriate advisory committee meeting at the location of the advisory the Federal Advisory Committee Act (5 link, or call the advisory committee committee meeting, and the background U.S.C. app. 2). information line to learn about possible material will be posted on FDA’s Web Additional Pediatric-focused Safety modifications before coming to the site after the meeting. Background Reviews: FDA will make available meeting. For press inquiries, please material will be available at http:// additional pediatric safety review contact the Office of Media Affairs at www.fda.gov/AdvisoryCommittees/ reports for selected products at http:// fdaoma@fda.hhs.gov or 301–796–4540. Calendar/default.htm. Scroll down to www.fda.gov/AdvisoryCommittees/ the appropriate advisory committee CommitteesMeetingMaterials/ SUPPLEMENTARY INFORMATION: Agenda: meeting link. PediatricAdvisoryCommittee/ On September 14, 2016, the Pediatric Procedure: Interested persons may ucm510701.htm. FDA is establishing a Advisory Committee (PAC) will meet to present data, information, or views, discuss pediatric-focused safety second public docket to receive input orally or in writing, on issues pending on additional pediatric-focused safety reviews, as mandated by the Best before the committee. Written Pharmaceuticals for Children Act (Pub. reviews that will be posted on the submissions may be made to the contact Internet. The docket number is FDA– L. 107–109) and the Pediatric Research person on or before September 7, 2016. Equity Act (Pub. L. 108–155). Comments 2016–N–2470; the docket will open on Oral presentations from the public will September 12, 2016, and remain open about the up-coming September be scheduled between approximately advisory committee meeting should be until September 23, 2016. These safety 8:30 a.m. to 9:30 a.m. Those individuals review reports are for the following submitted to Docket No. FDA–2016–N– interested in making formal oral 0567. products: presentations should notify the contact 1. BARACLUDE (entecavir) The PAC will meet to discuss the person and submit a brief statement of following products (listed by FDA 2. ISENTRESS (raltegravir potassium) the general nature of the evidence or 3. LYSTEDA (tranexamic acid) Center): arguments they wish to present, the 4. SALONPAS Pain Relief Patch (methyl 1. Center for Biologics Evaluation and names and addresses of proposed salicylate 10% and l-menthol 3%). Research participants, and an indication of the a. MENVEO (Meningococcal (groups Dated: August 11, 2016. approximate time requested to make A, C, Y and W–135) their presentation on or before August Janice M. Soreth, Oligosaccharide Diphtheria 30, 2016. Time allotted for each Acting Associate Commissioner, Special CRM197 Conjugate Vaccine) presentation may be limited. If the Medical Programs. b. IXIARO (Japanese encephalitis number of registrants requesting to [FR Doc. 2016–19589 Filed 8–16–16; 8:45 am] vaccine) speak is greater than can be reasonably BILLING CODE 4164–01–P 2. Center for Drug Evaluation and accommodated during the scheduled Research open public hearing session, FDA may a. ASACOL & ASACOL HD conduct a lottery to determine the DEPARTMENT OF HEALTH AND (mesalamine) speakers for the scheduled open public HUMAN SERVICES b. BLOXIVERZ (neostigmine hearing session. The contact person will methylsulfate) Indian Health Service notify interested persons regarding their c. DELZICOL (mesalamine) request to speak by August 31, 2016. National Indian Health Outreach and d. DORYX (doxycycline hyclate) Persons attending FDA’s advisory e. KARBINAL ER (carbinoxamine Education II Program; Correction committee meetings are advised that the maleate) Agency is not responsible for providing AGENCY: Indian Health Service, HHS. f. KEPIVANCE (palifermin) access to electrical outlets. ACTION: Notice; correction. g. SUSTIVA (efavirenz) FDA is establishing a docket for h. TOPAMAX (topiramate) public comment for the PAC meeting. SUMMARY: The Indian Health Service i. XOLAIR (omalizumab) The docket number is FDA–2016–N– published a document in the Federal 3. Center for Devices and Radiological 0567. The docket will close on August Register on July 15, 2016, for the Fiscal Health 31, 2016. Comments received on or Year 2016 National Indian Health a. ELANA SURGICAL KIT (HUD) before August 31, 2016, will be Outreach and Education II Program. The b. BERLIN HEART EXCOR® Pediatric provided to the committee. Comments notice contained an incorrect mstockstill on DSK3G9T082PROD with NOTICES Ventricular Assist Device (VAD) received after the date will be taken into Announcement Number. c. ENTERRATM THERAPY SYSTEM consideration by the Agency. FOR FURTHER INFORMATION CONTACT: Ms. d. CONTEGRA PULMONARY FDA welcomes the attendance of the Michelle EagleHawk, Deputy Director, VALVED CONDUIT public at its advisory committee Office of Direct Service and Contracting e. PLEXIMMUNE meetings and will make every effort to Tribes, 5600 Fishers Lane, Mail Stop: FDA will also provide an update of accommodate persons with disabilities. 8E17, Rockville, Maryland 20857, their additional ongoing analysis of a If you require accommodations due to a Telephone: (301) 443–1104, email: VerDate Sep<11>2014 16:39 Aug 16, 2016 Jkt 238001 PO 00000 Frm 00029 Fmt 4703 Sfmt 4703 E:\FR\FM\17AUN1.SGM 17AUN1

Federal Register / Vol. 81, No. 159 / Wednesday, August 17, 2016 / Notices 54815 Michelle.EagleHawk@ihs.gov. (This is Contact Person: Bita Nakhai, Ph.D., individuals associated with the grant not a toll-free number.) Scientific Review Branch, National Institute applications, the disclosure of which on Aging, Gateway Bldg., 2C212, 7201 would constitute a clearly unwarranted Correction Wisconsin Avenue, Bethesda, MD 20814, 301–402–7701, nakhaib@nia.nih.gov. invasion of personal privacy. In the Federal Register of July 15, Name of Committee: National Center for 2016, FR Doc. 2016–16819, on page Name of Committee: National Institute on Aging Special Emphasis Panel; NIH Phase III Advancing Translational Sciences Special 46100, in the second column at the top Clinical Trials for Alzheimer’s Disease and Emphasis Panel; CTSA Review. of the page, the correct Announcement Other Age-Related Cognitive Declines. Date: September 22–23, 2016. Number should read as follows: Date: October 13, 2016. Time: 8:00 a.m. to 2:30 p.m. Announcement Number: HHS–2016– Time: 12:01 p.m. to 5:00 p.m. Agenda: To review and evaluate grant IHS–NIHOE–2–BH–HIV–AIDS–0001. Agenda: To review and evaluate grant applications. applications. Place: Hilton Washington DC/Rockville Dated: August 4, 2016. Hotel, Plaza 2 and 3, 1750 Rockville Pike, Place: National Institute on Aging, Elizabeth A. Fowler, Gateway Building, Suite 2W200, 7201 Rockville, MD 20852. Deputy Director for Management Operations, Wisconsin Avenue, Bethesda, MD 20892 Contact Person: Carol Lambert, Ph.D., Indian Health Service. (Telephone Conference Call). Acting Deputy Director, Office of Scientific [FR Doc. 2016–19597 Filed 8–16–16; 8:45 am] Contact Person: Maurizio Grimaldi, MD, Review, National Center for Advancing Ph.D., Scientific Review Officer, National Translational Sciences (NCATS), National BILLING CODE 4165–16–P Institute on Aging, National Institutes of Institutes of Health, 6701 Democracy Blvd., Health, 7201 Wisconsin Avenue, Room Democracy 1, Room 1076, Bethesda, MD 2C218, Bethesda, MD 20892, 301–496–9374, 20892, 301–435–0814, lambert@mail.nih.gov. DEPARTMENT OF HEALTH AND grimaldim2@mail.nih.gov. (Catalogue of Federal Domestic Assistance HUMAN SERVICES Program Nos. 93.859, Pharmacology, Name of Committee: National Institute on Aging Special Emphasis Panel; Alzheimer’s Physiology, and Biological Chemistry National Institutes of Health Research; 93.350, B—Cooperative Disease Drug Development. Date: October 14, 2016. Agreements; 93.859, Biomedical Research National Institute on Aging; Notice of Time: 12:00 p.m. to 4:00 p.m. and Research Training, National Institutes of Closed Meetings Agenda: To review and evaluate grant Health, HHS) Pursuant to section 10(d) of the applications. Dated: August 11, 2016. Place: National Institute on Aging, Federal Advisory Committee Act, as David Clary, Gateway Building, Suite 2W200, 7201 amended (5 U.S.C. App.), notice is Wisconsin Avenue, Bethesda, MD 20892 Program Analyst, Office of Federal Advisory hereby given of the following meetings. (Telephone Conference Call). Committee Policy. The meetings will be closed to the Contact Person: Alexander Parsadanian, [FR Doc. 2016–19542 Filed 8–16–16; 8:45 am] public in accordance with the Ph.D., Scientific Review Officer, National BILLING CODE 4140–01–P provisions set forth in sections Institute on Aging, Gateway Building 2C/212, 552b(c)(4) and 552b(c)(6), title 5 U.S.C., 7201 Wisconsin Avenue, Bethesda, MD as amended. The grant applications and 20892, 301–496–9666, parsadaniana@nia.nih.gov. DEPARTMENT OF HEALTH AND the discussions could disclose HUMAN SERVICES confidential trade secrets or commercial (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, property such as patentable material, National Institutes of Health National Institutes of Health, HHS). and personal information concerning individuals associated with the grant Dated: August 11, 2016. National Cancer Institute; Notice of applications, the disclosure of which Melanie J. Gray, Meeting would constitute a clearly unwarranted Program Analyst, Office of Federal Advisory Pursuant to section 10(a) of the invasion of personal privacy. Committee Policy. Federal Advisory Committee Act, as Name of Committee: National Institute on [FR Doc. 2016–19547 Filed 8–16–16; 8:45 am] amended (5 U.S.C. App.), notice is Aging Special Emphasis Panel; Worm BILLING CODE 4140–01–P hereby given of a meeting of the Intervention Test Data Sharing. National Cancer Institute Clinical Trials Date: September 19, 2016. and Translational Research Advisory Time: 3:00 p.m. to 3:30 p.m. DEPARTMENT OF HEALTH AND Agenda: To review and evaluate grant Committee. HUMAN SERVICES The meeting will be open to the applications. Place: National Institute on Aging, National Institutes of Health public, with attendance limited to space Gateway Building, 2W200, 7201 Wisconsin available. Individuals who plan to Avenue, Bethesda, MD 20892 (Telephone National Center for Advancing attend and need special assistance, such Conference Call). Translational Sciences; Notice of as sign language interpretation or other Contact Person: Bita Nakhai, Ph.D., Closed Meeting reasonable accommodations, should Scientific Review Branch, National Institute notify the Contact Person listed below on Aging, Gateway Bldg., 2C212, 7201 Pursuant to section 10(d) of the in advance of the meeting. The meeting Wisconsin Avenue, Bethesda, MD 20814, Federal Advisory Committee Act, as will also be videocast and can be 301–402–7701, nakhaib@nia.nih.gov. amended (5 U.S.C. App.), notice is accessed from the NIH Videocasting and Name of Committee: National Institute on hereby given of the following meeting. Podcasting Web site (http:// Aging Special Emphasis Panel; Worm The meeting will be closed to the Intervention Test One. videocast.nih.gov/). public in accordance with the mstockstill on DSK3G9T082PROD with NOTICES Date: September 19, 2016. provisions set forth in sections Name of Committee: National Cancer Time: 12:00 p.m. to 3:00 p.m. 552b(c)(4) and 552b(c)(6), title 5 U.S.C., Institute Clinical Trials and Translational Agenda: To review and evaluate grant Research Advisory Committee. applications. as amended. The grant applications and Date: November 2, 2016. Place: National Institute on Aging, the discussions could disclose Time: 8:00 a.m. to 4:00 p.m. Gateway Building, 2W200, 7201 Wisconsin confidential trade secrets or commercial Agenda: Strategic Discussion of NCI’s Avenue, Bethesda, MD 20892 (Telephone property such as patentable material, Clinical and Translational Research Conference Call). and personal information concerning Programs. VerDate Sep<11>2014 16:39 Aug 16, 2016 Jkt 238001 PO 00000 Frm 00030 Fmt 4703 Sfmt 4703 E:\FR\FM\17AUN1.SGM 17AUN1


Document Created: 2018-02-09 11:34:52
Document Modified: 2018-02-09 11:34:52
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice; correction.
ContactMs. Michelle EagleHawk, Deputy Director, Office of Direct Service and Contracting Tribes, 5600 Fishers Lane, Mail Stop: 8E17, Rockville, Maryland 20857, Telephone: (301) 443- 1104, email: [email protected] (This is not a toll-free number.)
FR Citation81 FR 54814 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR